Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The glycosylation of the circulating immunoglobulin-gamma (IgG) antibody molecules changes in rheumatoid arthritis. The extent of the changes correlates with the disease severity and reverses in remission. We demonstrate here that the alteration in glycosylation associated with rheumatoid arthritis can create a new mode for the interaction of IgG with complement through binding to the collagenous lectin mannose-binding protein (MBP). Rheumatoid arthritis is associated with a marked increases in IgG glycoforms that lack galactose (referred to as G0 glycoforms) in the Fc region of the molecule and that terminate in N-acetyl glucosamine (GlcNAc). We show, using nuclear magnetic resonance (NMR) and X-ray data, that these terminal GlcNAc residues become accessible for MBP binding. We further demonstrate that multiple presentation of IgG-G0 glycoforms to MBP results in activation of the complement. This suggests that a contribution to the chronic inflammation of the synovial membrane could arise from the localization of the IgG-G0 glycoforms in the affected joint and from resulting activation of complement.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Modified Spin-Echo Method for Measuring Nuclear Relaxation Times
Meiboom, S., & Gill, D. (1958) · Review of Scientific Instruments · doi:10.1063/1.1716296 · Cited by 6,022
The hydrolysis of rabbit γ-globulin and antibodies with crystalline papain
Porter, R. R. (1959) · Biochemical Journal · doi:10.1042/bj0730119 · Cited by 2,308
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Self-citationStructure of a C-type mannose-binding protein complexed with an oligosaccharide
Weis, W. I., Drickamer, K., & Hendrickson, W. A. (1992) · Nature · doi:10.1038/360127a0 · Cited by 885
The binding site for C1q on IgG
Duncan, A. R., & Winter, G. (1988) · Nature · doi:10.1038/332738a0 · Cited by 569
Drickamer, K., Dordal, M. S., & Reynolds, L. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)62698-0 · Cited by 429
Serum lectin with known structure activates complement through the classical pathway.
Ikeda, K., Sannoh, T., Kawasaki, N., Kawasaki, T., & Yamashina, I. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47587-4 · Cited by 424
Trimeric structure of a C-type mannose-binding protein
Weis, W. I., & Drickamer, K. (1994) · Structure · doi:10.1016/s0969-2126(94)00124-3 · Cited by 307
Research works printed but not linked: 2
- Chang, S.-C. Altered Glycosylation in Immunoglobulin G and Its Fragments in Rheumatoid Arthritis. thesis, Oxford (1993).
- Parekh, R.B. A Study of the Structure and Biosynthesis of N-linked Oligosaccharides and of their Involvement in Certain Diseases. thesis, Oxford Univ.(1987).
Cited by
Items 201–300 of 844
Interactions of Immunoglobulins Outside the Antigen-Combining Site
Nezlin, R. S., & Ghetie, V. F. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)82004-2 · Cited by 86
Macrophage Membrane Molecules: Markers of Tissue Differentiation and Heterogeneity
Martínez‐Pomares, L., Platt, N., Mcknight, A. J., da Silva, R. P., & Gordon, S. (1996) · Immunobiology · doi:10.1016/s0171-2985(96)80012-x · Cited by 85
Shinzaki, S., Iijima, H., Nakagawa, T., Egawa, S., Nakajima, S., Ishii, S., Irie, T., Kakiuchi, Y., Nishida, T., Yasumaru, M., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01699.x · Cited by 84
“Agalactosyl IgG either activates the complement pathway or directly activates macrophages after binding to either mannose-binding lectin or mannose receptors, respectively”
BackgroundMannose-binding lectin and rheumatoid arthritis in Southern Chinese
Ip, W., Lau, Y., Chan, S. Y., Mok, C. C., Chan, D. T.-M., Tong, K. K., & Lau, C. S. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8<1679::aid-anr3>3.0.co;2-d · Cited by 84
Activities of the MBL-associated serine proteases (MASPs) and their regulation by natural inhibitors
Wong, N., Kojima, M., Dobó, J., Ambrus, G., & Sim, R. B. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00106-6 · Cited by 84
Self-citationNaturally Occurring Structural Isomers in Serum IgA1 O -Glycosylation
Takahashi, K., Smith, A. D., Poulsen, K., Kilian, M., Julian, B. A., Mestecky, J. F., Novák, J., & Renfrow, M. B. (2011) · Journal of Proteome Research · doi:10.1021/pr200608q · Cited by 83
Banda, N. K., Wood, A., Takahashi, K., Levitt, B., Rudd, P. M., Royle, L., Abrahams, J. L., Stahl, G. L., Holers, V. M., & Arend, W. P. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23865 · Cited by 83
Self-citationEspéli, M., Smith, K. G. C., & Clatworthy, M. R. (2015) · Immunological Reviews · doi:10.1111/imr.12368 · Cited by 83
“G0 IgG (in immunecomplexed form) can activate complement via binding to mannose-binding lectin (12) and can bind the mannose receptor on phagocytes (13), while the presence of a terminal sialic acid significantly reduces binding to FccRs (14, 15) and allows binding to the c-type lectin receptor, SIGNR1 (4).”
BackgroundRussell, A. C., Adua, E., Ugrina, I., Laws, S. M., & Wang, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020390 · Cited by 84
“These beneficial effects are well-established and have been harnessed in the form of intravenous immunoglobulin therapy in On the contrary, there are examples where these effects are detrimental, such as in rheumatoid arthritis patients [5–7].”
Ying, H., Ji, X., Hart, M. L., Gupta, K., Saifuddin, M., Zariffard, M. R., & Spear, G. T. (2004) · AIDS Research and Human Retroviruses · doi:10.1089/088922204322996563 · Cited by 83
“Since both MBL and antiviral antibodies have been shown to bind to HIV gp120 and since MBL has been reported to interact with carbohydrates on antibodies, 38 we next determined if MBL and antibodies could additively or synergistically mediate neutralization.”
Controlled glycosylation of therapeutic antibodies in plants
Tekoah, Y., Ko, K., Koprowski, H., Harvey, D. J., Wormald, M. R., Dwek, R. A., & Rudd, P. M. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.02.034 · Cited by 82
Self-citationMultiplexed Analytical Glycomics: Rapid and Confident IgG N-Glycan Structural Elucidation
Mittermayr, S., Bones, J., Doherty, M., Guttman, A., & Rudd, P. M. (2011) · Journal of Proteome Research · doi:10.1021/pr200371s · Cited by 75
Self-citationGlomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy
Hayashi, N., Okada, K., Matsui, Y., Fujimoto, K., Adachi, H., Yamaya, H., Matsushita, M., & Yokoyama, H. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx235 · Cited by 82
Subedi, G. P., Hanson, Q. M., & Barb, A. W. (2014) · Structure · doi:10.1016/j.str.2014.08.002 · Cited by 81
“Based on recent reports (Barb et al., 2012; Barb and Prestegard, 2011; Frank et al., 2014; Krapp et al., 2003; Malhotra et al., 1995; Yamaguchi et al., 1998), we propose that conformational oscillations of the Fc Cγ2 domains and N-glycans are integral to FcγR binding and vary between naturally occurring glycoforms.”
BackgroundThe carbohydrate switch between pathogenic and immunosuppressive antigen‐specific antibodies
Collin, M., & Ehlers, M. (2013) · Experimental Dermatology · doi:10.1111/exd.12171 · Cited by 73
The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease
Defendi, F., Thielens, N. M., Clavarino, G., Cesbron, J.-Y., & Dumestre‐Pérard, C. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08774-5 · Cited by 82
Towards a Liquid Self: How Time, Geography, and Life Experiences Reshape the Biological Identity
Grignolio, A., Mishto, M., Faria, A. M. C., Garagnani, P., Franceschi, C., & Tieri, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00153 · Cited by 73
Galactosemia, a Single Gene Disorder With Epigenetic Consequences
Coman, D. J., Murray, D. W., Byrne, J. C., Rudd, P. M., Bagaglia, P. M., Doran, P., & Treacy, E. P. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e3181cbd542 · Cited by 78
Self-citationSweet and sour: the impact of sugars on disease
Alavi, A., & Axford, J. S. (2008) · Rheumatology · doi:10.1093/rheumatology/ken081 · Cited by 78
Complement-related serine proteases in tunicates and vertebrates
Matsushita, M., Endo, Y., Nonaka, M., & Fujita, T. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80027-7 · Cited by 78
Glycosylation as a marker for inflammatory arthritis
Albrecht, S., Unwin, L., Muniyappa, M., & Rudd, P. M. (2014) · Cancer Biomarkers · doi:10.3233/cbm-130373 · Cited by 76
“Hypogalactosylated IgG interacts with lectin-like molecules, such as mannose-binding protein, which activates a complement pathway leading to inflammatory response [61,62].”
Self-citationMurata, K., Fox-Talbot, K., Qian, Z., Takahashi, K., Stahl, G. L., Baldwin, W. M., & Wasowska, B. A. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01971.x · Cited by 76
“(25) previously reported that certain circulating IgG molecules in patients with rheumatoid arthritis can activate complement through the MBL pathway.”
BackgroundFc Glycans Terminated with N-Acetylglucosamine Residues Increase Antibody Resistance to Papain
Raju, T. S., & Scallon, B. J. (2007) · Biotechnology Progress · doi:10.1021/bp070118k · Cited by 76
Heterogeneity of O-glycosylation in the hinge region of human IgA1
Novák, J., Tomana, M., Kilian, M., Coward, L. U., Kulhavy, R., Barnes, S., & Mestecky, J. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00019-0 · Cited by 76
“For example, the functional deficiency of 1,4 galactosyltransferase in IgG-producing cells appears to be responsible for deficiency of Gal in N-linked side chains of IgG molecules isolated from sera of patients with rheumatoid arthritis or inflammatory bowel disease (Axford et al., 1987; Dube et al., 1990; Furukawa et…”
BackgroundYamaguchi, Y., Kato, K., Shindo, M., Aoki, S., Furusho, K., Koga, K., Takahashi, N., Arata, Y., & Shimada, I. (1998) · Journal of Biomolecular NMR · doi:10.1023/a:1008392229694 · Cited by 76
Complement-mediated kidney diseases
Poppelaars, F., & Thurman, J. M. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.10.015 · Cited by 75
The association between galactosylation of immunoglobulin G and body mass index
Perković, M. N., Pučić‐Baković, M., Krištić, J., Novokmet, M., Huffman, J. E., Vitart, V., Hayward, C., Rudan, I., Wilson, J. F., Campbell, H. J., et al. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.014 · Cited by 74
“Post-translational modifications of IgG molecules by glycosylation, defined by the attachment of oligosaccharides, are important for structural integrity of IgGmolecules and they play a crucial role in activation of complement (Malhotra et al., 1995), in interactions with Fc receptors (Adler et al.”
InfluentialBartsch, Y. C., Rahmöller, J., Mertes, M. M. M., Eiglmeier, S., Lorenz, F. K. M., Stoehr, A. D., Braumann, D., Lorenz, A., Winkler, A., Lilienthal, G., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01183 · Cited by 75
Saevarsdottir, S., Vikingsdottir, T., & Valdimarsson, H. (2004) · Scandinavian Journal of Immunology · doi:10.1111/j.0300-9475.2004.01437.x · Cited by 70
Wang, M., Zhang, Y., Chen, Y., Zhang, L., Lu, X., & Chen, Z. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-1 · Cited by 74
“MBL is also present in such extravascular milieux as synovial fluid, amniotic fluid, lung and vaginal lavages [45-49], and behaves as an acute-phase reactant in individuals with ‘sufficient’ (wild-type) MBL genotypes [50].”
BackgroundCorrelates of immune exacerbations in leprosy
Geluk, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.06.003 · Cited by 76
Yuan, W., Šanda, M., Wu, J., Koomen, J. M., & Goldman, R. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2014.12.020 · Cited by 73
Glycosylation Profile of IgG in Moderate Kidney Dysfunction
Barrios, C. P., Zierer, J., Gudelj, I., Štambuk, J., Ugrina, I., Rodríguez, E., Soler, M. J., Štambuk, T., Šimurina, M., Keser, T., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010109 · Cited by 71
Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid
Yehuda, S., & Padler-Karavani, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00021 · Cited by 71
“In addition, higher presence of galactose promotes complementdependent cytotoxicity, while decreased galactosylation leads to alternative complement cascade activation (32, 33).”
BackgroundImmunological mechanism of IgG4-related disease
Liu, C., Zhang, P., & Zhang, W. (2020) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2020.100047 · Cited by 72
“Recent studies also showed that the agalactosylated IgG acts as an epitope for complement-activating mannose-binding lectins resulting in activation of the lectin complement pathway [15].”
BackgroundOgata, S., Shimizu, C., Franco, A., Touma, R., Kanegaye, J. T., Choudhury, B. P., Naidu, N. N., Kanda, Y., Hoang, L. T., Hibberd, M. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081448 · Cited by 66
“IgG glycan modifications such as addition of sialic acid (Sia), galactose (Gal) or fucose, in serum IgG is associated with different inflammatory and immune system diseases, including rheumatoid arthritis and myasthenia gravis [10,11].”
BackgroundResolving Isomeric Glycopeptide Glycoforms with Hydrophilic Interaction Chromatography (HILIC)
Huang, Y., Nie, Y., Boyes, B. E., & Orlando, R. (2016) · Journal of Biomolecular Techniques JBT · doi:10.7171/jbt.16-2703-003 · Cited by 71
“Alteration of glycosylation is associated with various human pathologies, such as cancers,(6) Alzheimer’s disease,(7) and rheumatoid arthritis.(8) Consequently, the analysis of protein glycosylation is necessary to improve our”
BackgroundImproving Antibody-Based Cancer Therapeutics Through Glycan Engineering
Yu, X., Marshall, M. J. E., Cragg, M. S., & Crispin, M. (2017) · BioDrugs · doi:10.1007/s40259-017-0223-8 · Cited by 71
“The first clinical association was noted in rheumatoid arthritis patients, where a lack of terminal galactose in the IgG Fc glycoforms was correlated with disease induction, suggesting a pro-inflammatory role of agalactosylated glycoforms [36].”
BackgroundŠtambuk, T., Dilber, D., Kifer, D., Selak, N., Keser, T., Ljubičić, Đ., Dugac, A. V., Lauc, G., Rumora, L., & Gornik, O. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1695-0 · Cited by 70
Jack, D. L., Lee, M. E., TURNER, M. W., Klein, N. J., & Read, R. C. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0604342 · Cited by 70
“Although MBL is present at extravascular sites [36] and is present in the airways of mice infected by influenza virus [37], it is unlikely to be present at concentrations sufficient to saturate the meningococcal surface to the exclusion of SR-A in”
BackgroundMechanisms of action of intravenous immunoglobulins
Baerenwaldt, A., Biburger, M., & Nimmerjahn, F. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.9 · Cited by 71
N-glycans as functional effectors of genetic and epigenetic disease risk
Štambuk, T., Klasić, M., Zoldoš, V., & Lauc, G. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100891 · Cited by 70
Yoo, E. M., Chintalacharuvu, K. R., Penichet, M. L., & Morrison, S. L. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00559-2 · Cited by 69
Biessen, E. L., Noorman, F., van Teijlingen, M. E., Kuiper, J., Barrett-Bergshoeff, M. M., Bijsterbosch, M. K., Rijken, D. C., & van Berkel, T. J. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28024 · Cited by 69
A Perspective on the Structure and Receptor Binding Properties of Immunoglobulin G Fc
Hanson, Q., & Barb, A. W. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00299 · Cited by 68
Mannose-Binding Lectin Contributes to the Severity of Guillain-Barré Syndrome
Geleijns, K. P. W., Roos, A., Houwing‐Duistermaat, J. J., van Rijs, W., Tio‐Gillen, A. P., Laman, J. D., van Doorn, P. A., & Jacobs, B. C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.4211 · Cited by 67
Dreja, H. S., Annenkov, A. E., & Chernajovsky, Y. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8<1698::aid-anr5>3.0.co;2-8 · Cited by 68
The Role of Secretory IgA and Complement in IgA Nephropathy
Oortwijn, B. D., Eijgenraam, J., Rastaldi, M.-P., Roos, A., Daha, M. R., & van Kooten, C. (2008) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.10.007 · Cited by 67
Antiviral activity of bovine collectins against rotaviruses.
Reading, P. C., Holmskov, U., & Anders, E. M. (1998) · Journal of General Virology · doi:10.1099/0022-1317-79-9-2255 · Cited by 67
“Furthermore, transudation of MBL into inflammatory sites such as the rheumatoid joint (Malhotra et al., 1995) or the influenza virus-infected lung (Reading et al.”
BackgroundPeters, C., Kawakami, M., Kaul, M., Ilg, T., Overath, P., & Aebischer, T. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271028 · Cited by 67
Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice
Newkirk, M. M., Novick, J., Stevenson, M. M., Fournier, M.-J., & Apostolakos, P. (2003) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1996.d01-847.x · Cited by 61
Stable-isotope-assisted NMR approaches to glycoproteins using immunoglobulin G as a model system
Kato, K., Yamaguchi, Y., & Arata, Y. (2010) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2010.03.001 · Cited by 66
Troelsen, L. N., Garred, P., MADSEN, H. O., & Jacobsen, S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22302 · Cited by 66
Glycoproteins: Structure and Function
Sharon, N., & Lis, H. (1996) · Wiley eBooks · doi:10.1002/9783527614738.ch8 · Cited by 66
Jimenez del Val, I., Fan, Y., & Weilguny, D. (2016) · Biotechnology Journal · doi:10.1002/biot.201400663 · Cited by 62
“Furthermore, antibodies bearing this glycan have been associated with detrimental inflammatory responses in humans [17].”
BackgroundPham, C. T. N., Thomas, D., Beiser, J. A., Mitchell, L. M., Huang, J. L., Senpan, A., Hu, G., Gordon, M. O., Baker, N., Pan, D., et al. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.10.012 · Cited by 64
Plasma N-Glycome Signature of Down Syndrome
Borelli, V., Vanhooren, V., Lonardi, E., Reiding, K. R., Capri, M., Libert, C., Garagnani, P., Salvioli, S., Franceschi, C., & Wuhrer, M. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00356 · Cited by 60
Glycosylation and Placental Transport of Immunoglobulin G.
KIBE, T., FUJIMOTO, S., ISHIDA, C., TOGARI, H., WADA, Y., OKADA, S., NAKAGAWA, H., TSUKAMOTO, Y., & TAKAHASHI, N. (1996) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.21.57 · Cited by 63
“It is well known that decreased galactosylation of IgG contributes to molecular pathogenesis in rheumatoid arthritis (RA) [12, 13].”
BackgroundMannan binding lectin deficiency and concomitant immunodefects
Aittoniemi, J., Baer, M., Soppi, E. T., Vesikari, T., & Miettinen, A. (1998) · Archives of Disease in Childhood · doi:10.1136/adc.78.3.245 · Cited by 63
Factors affecting IgG4-mediated complement activation
Oskam, N., Damelang, T., Streutker, M., Heer, P. O., Nouta, J., Koeleman, C. A. M., Coillie, J. V., Wuhrer, M., Vidarsson, G., & Rispens, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1087532 · Cited by 62
“It has been suggested that IgG antibodies lacking the terminal galactose residue on their Fc-glycan could activate complement via the lectin pathway, as MBL can bind to terminal fucose, mannose and Nacetylglucosamine residues, but not galactose (29).”
BackgroundBiosimilars entering the clinic without animal studies: A paradigm shift in the European Union
van Aerts, L., Smet, K. D., Reichmann, G., van der Laan, J. W., & Schneider, C. K. (2014) · mAbs · doi:10.4161/mabs.29848 · Cited by 62
“Other examples where different glycoforms affect functionality are IgGs containing glycans lacking terminal sialic acid and galactose and terminating in N-acetyl glucosamine (GlcNAc) being capable of binding mannose-binding lectin, which leads to activation of the lectin pathway of complement activation.(33) Alternati…”
BackgroundGardinassi, L. G., Dotz, V., Ederveen, A. L. H., de Almeida, R. P., Costa, C. H. N., Costa, D. L., de Jesus, A. R., Mayboroda, O. A., Garcia, G. R., Wuhrer, M., et al. (2014) · mBio · doi:10.1128/mbio.01844-14 · Cited by 62
“The abundance of terminal Fc galactose residues strongly influences the interaction of IgG with cellular receptors and MBL (20, 24, 58), which is thought to be a disease-enhancing opsonin for intracellular pathogens (59, 60).”
BackgroundInfluentialBorza, D. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00157 · Cited by 63
“MBL binds to “G0” glycoforms of IgG that lack terminal sialic and galactose residues on the conserved N-glycan in the Fc region, activating the LP (44).”
BackgroundGlycosylation Alterations in Multiple Sclerosis Show Increased Proinflammatory Potential
Cvetko, A., Kifer, D., Gornik, O., Klarić, L., Visser, E. M., Lauc, G., Wilson, J. F., & Štambuk, T. (2020) · Biomedicines · doi:10.3390/biomedicines8100410 · Cited by 62
Changes in serum IgG oligosaccharide chains with prostate cancer progression.
Kanoh, Y., Mashiko, T., Danbara, M., Takayama, Y., Ohtani, S., Egawa, S., Baba, S., & Akahoshi, T. (2004) · PubMed · Cited by 62
Fc Glycan-Modulated Immunoglobulin G Effector Functions
Quast, I., & Lünemann, J. D. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0018-3 · Cited by 61
“The first suggested mechanism for a functional consequence of galactosylation was based on the in vitro finding that galactosylation prevents binding of the initiator of the lectin pathway of the complement system, mannose binding lectin (MBL) [31].”
BackgroundMechanisms involved in antibody- and complement-mediated allograft rejection
Wasowska, B. A. (2010) · Immunologic Research · doi:10.1007/s12026-009-8136-3 · Cited by 61
“[81] previously reported that certain circulating IgG molecules in patients with rheumatoid arthritis can activate complement through the MBL pathway.”
BackgroundOld dogs—new tricks: immunoregulatory properties of C3 and C5 cleavage fragments
Verschoor, A., Karsten, C. M., Broadley, S. P., Laumonnier, Y., & Köhl, J. (2016) · Immunological Reviews · doi:10.1111/imr.12473 · Cited by 61
Mucosa–Environment Interactions in the Pathogenesis of Rheumatoid Arthritis
Lucchino, B., Spinelli, F. R., Iannuccelli, C., Guzzo, M. P., Conti, F., & Franco, M. D. (2019) · Cells · doi:10.3390/cells8070700 · Cited by 64
“In fact, a reduced terminal galactosylation increases the complement-fixing activity of the IgG, while an increased fucosylation of the Fc region changes the a nity for the various Fc receptors [113].”
BackgroundProduction of Antibodies in Plants: Approaches and Perspectives
Ko, K. S., Brodzik, R., & Steplewski, Z. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70868-1_4 · Cited by 61
“In glycosylation, lack of galactose decreases the half-life through binding of agalactosyl IgG to mannose-binding protein or mannose receptors ( Malhotra et al. 1995; Wright and Morrison 1998).”
BackgroundYang, Y., Wang, C., Jin, L., He, F.-G., Li, C., Gao, Q., Chen, G., He, Z., Song, M., Zhou, Z., et al. (2016) · Immunologic Research · doi:10.1007/s12026-016-8790-1 · Cited by 60
“Besides, IgG4 might injure podocytes in other pathological ways rather than direct complement injury and it could not be excluded that IgG4 had other important immunomodulatory or pathophysiological functions [9, 25].”
BackgroundReiding, K. R., Vreeker, G. C. M., Bondt, A., Bladergroen, M. R., Hazes, J. M. W., van der Burgt, Y. E. M., Wuhrer, M., & Dolhain, R. J. E. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2017.00241 · Cited by 62
Multiple Roles of Glycans in Hematological Malignancies
Pang, X., Li, H., Guan, F., & Li, X. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00364 · Cited by 60
“Galactose (Gal) residues are absent from total serum IgG of rheumatoid arthritis patients (5), and this altered glycosylation state activates complement via mannose-binding protein (6).”
BackgroundSolution structure of the glycosylated second type 2 module of fibronectin
Sticht, H., Pickford, A. R., Potts, J. R., & Campbell, I. D. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1528 · Cited by 60
“The fact that different glycoforms of a protein may display quite different orientations of the oligosaccharides with respect to the polypeptide has been reported previously for the Fc fragment of IgG (Deisenhofer, 1981; Malhotra et al., 1995).”
BackgroundComplement activation in early protocol kidney graft biopsies after living-donor transplantation1
Sund, S., Hovig, T., Reisæter, A. V., Scott, H., Bentdal, Ø. H., & Mollnes, T. E. (2003) · Transplantation · doi:10.1097/01.tp.0000062835.30165.2c · Cited by 60
Scanlan, C. N., Burton, D. R., & Dwek, R. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801192105 · Cited by 59
Self-citationHansen, T. K., Thiel, S., Dall, R., Rosenfalck, A. M., Trainer, P. J., Flyvbjerg, A., Jørgensen, J. O. L., & Christiansen, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8009 · Cited by 59
“MBL does not normally recognize the body’s own tissues (27), but it has recently been reported that cellular hypoxia may alter cell surface glycosylation, leading to increased MBL deposition and complement activation (14).”
Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn’s disease
Rector, A., Lemey, P., Laffut, W., Keyaerts, E., Struyf, F., Wollants, E., Vermeire, S., Rutgeerts, P., & Ranst, M. A. V. (2001) · Genes and Immunity · doi:10.1038/sj.gene.6363784 · Cited by 59
“24 Aggregated agalactosyl IgG can function as a ligand for MBL, thus initiating complement activation”
Raju, T. S. (2003) · Cited by 59
Happonen, K. E., Heinegård, D. K., Saxne, T., & Blom, A. M. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.013 · Cited by 58
“These IgG glycoforms have shown an increased affinity for MBL and may trigger lectin pathway activation in the joint (Malhotra et al., 1995).”
BackgroundNew Insights into Adaptive Immunity in Chronic Neuroinflammation
Siffrin, V., Brandt, A. U., Herz, J., & Zipp, F. (2007) · Advances in immunology · doi:10.1016/s0065-2776(07)96001-0 · Cited by 58
Babovic‐Vuksanovic, D., Snow, K., & TEN, R. M. (1999) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)62586-0 · Cited by 58
Ma, H., Xu, Y., Zhang, R., Guo, B., Zhang, S., & Zhang, X. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.84690 · Cited by 57
“Previous evidence suggests that PLA2R-IgG4 can play a role by activating the complement lectin pathway with MBL [29].”
BackgroundIn vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase
Warnock, D., Bai, X., Autote, K., Gonzales, J., Kinealy, K., Yan, B., Qian, J., Stevenson, T., Zopf, D., & Bayer, R. J. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20658 · Cited by 53
Beneden, K. V., Coppieters, K. T., Laroy, W., Keyser, F. D., Hoffman, I. E. A., den Bosch, F. E. V., Cruyssen, B. V., Drennan, M. B., Jacques, P., Rottiers, P., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.089292 · Cited by 56
Mannan-binding lectin (MBL) in chickens: molecular and functional aspects
Laursen, S. B., & Nielsen, O. L. (2000) · Developmental & Comparative Immunology · doi:10.1016/s0145-305x(99)00066-x · Cited by 56
Hart, M. L., Saifuddin, M., & Spear, G. T. (2003) · Journal of General Virology · doi:10.1099/vir.0.18734-0 · Cited by 56
“However, although sparse, some terminal N-acetylglucosamine residues are normally present on N-linked complex structures including gp120 (Malhotra et al., 1995; Scanlan et al., 2002), and it is possible that removing sialic acid provides better access of MBL to these residues.”
BackgroundAberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don’t Know
Ohyama, Y., Renfrow, M. B., Novák, J., & Takahashi, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163467 · Cited by 55
“IgA production in humans is approximately 66 mg/kg/day, which is approximately twice that of IgG and 10 times that of IgM [43].”
BackgroundOn enzymatic remodeling of IgG glycosylation; unique tools with broad applications
Sjögren, J., Lood, R., & Naegeli, A. (2019) · Glycobiology · doi:10.1093/glycob/cwz085 · Cited by 54
“The exposure of terminal GlcNAc (so called G0 glycans) is elevated in rheumatoid arthritis and cause increased binding to mannose-binding lectin and is thought to contribute to the chronic inflammation through this pathway (Malhotra et al. 1995).”
BackgroundFont, J., Ramos‐Casals, M., Brito‐Zerón, P., Nardi, N. N., Ibanez, A., Suárez, B., Jiménez, S., Tàssies, D., García‐Criado, Á., Ros, E., et al. (2006) · Rheumatology · doi:10.1093/rheumatology/kel199 · Cited by 54
“The structural and functional characteristics of MBL may affect the susceptibility to thrombotic events, since MBL is capable of binding to certain phospholipids, oligosaccharide structures and glycosylated IgG [25–27].”
BackgroundGraudal, N. A. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740310004847 · Cited by 53
“Therefore, agalactosyl IgG-MBL activated complement may play a role in some patients with RA, as proposed by Malhotra and colleagues (53).”
BackgroundHo, C.-H., Chien, R., Cheng, P., Liu, J.-H., Liu, C., Su, C.-S., Wu, I., Li, I.-C., Tsai, H., Wu, S., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu388 · Cited by 53
“For example, galactosedeficient IgG (IgG-G0) activates the complement cascade by interacting with mannan-binding lectin [11].”
BackgroundMechanisms of complement lectin pathway activation and resistance by trypanosomatid parasites
Cestari, I. D. S., Osses, I. S. E., Schlapbach, L. J., Messias-Reason, I., & Ramirez, M. I. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.08.015 · Cited by 53
Complement C4 monitoring in the follow-up of chronic hepatitis C treatment
Dumestre‐Pérard, C., Ponard, D., Drouet, C., Leroy, V., Zarski, J., Dutertre, N., & Colomb, M. G. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01729.x · Cited by 53
Ammitzbøll, C. G., Thiel, S., Ellingsen, T., Deleuran, B. W., Jørgensen, A., Jensenius, J. C., & Stengaard‐Pedersen, K. (2011) · Rheumatology International · doi:10.1007/s00296-011-1879-x · Cited by 53
“MBL has once been measured in paired samples of SF and plasma, surprisingly reporting almost identical levels in plasma and SF [13].”
BackgroundImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies
Le, N. P. L., Bowden, T. A., Struwe, W. B., & Crispin, M. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.04.016 · Cited by 49
Microbiomic and Posttranslational Modifications as Preludes to Autoimmune Diseases
Opdenakker, G., Proost, P., & Damme, J. V. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.07.002 · Cited by 52
IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis
Lundström, S. L., Hensvold, A. H., Rutishauser, D., Klareskog, L., Ytterberg, A. J., Zubarev, R. A., & Catrina, A. I. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1389-7 · Cited by 52
“Because Fc galactosylation status has been linked to both regulation of the lectin complement pathway (via agalactosylated Fc glycans) [3] and the classical complement pathway (via galactosylated Fc glycans) [32, 33], we tested how these proteins (also analyzed in the same sera LC-MS/MS measurements) would correlate w…”
Sun, D., Hu, F., Gao, H., Song, Z., Xie, W., Wang, P., Shi, L., Wang, K., Li, Y., Huang, C., et al. (2019) · The Analyst · doi:10.1039/c8an02014k · Cited by 52
Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis
Fang, Q., Ou, J., & Nandakumar, K. S. (2019) · Mediators of Inflammation · doi:10.1155/2019/6363086 · Cited by 52
“Clustered IgG in the synovial cavity facilitates multiple presentation of G0 glycans to mannose-binding protein that can lead to complement activation [210], and the mannose-binding lectin activity and G0 glycans correlate with arthritis onset [217].”
Background
Metadata
- Authors
- Malhotra, R., Wormald, M. R., Rudd, P. M., Fischer, P. B., Dwek, R. A., & Sim, R. B.
- Affiliations
- University of Oxford (GB)
- Venue
- Nature Medicine
- Published
- 1995-03
- Volume
- 1
- Issue
- 3
- Pages
- 237-243
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2053863608
- Cited by
- 786
- References
- 33
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 21 · 2023: 17 · 2022: 34 · 2021: 29 · 2020: 25 · 2019: 32 · 2018: 35 · 2017: 34 · 2016: 32 · 2015: 27 · 2014: 36 · 2013: 36 · 2012: 29
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- rheumatoid arthritis, IgG glycosylation, mannose-binding protein, complement activation, Fc fragment, N-acetylglucosamine, synovitis, chronic inflammation
- MeSH terms
- Arthritis, Rheumatoid, Carbohydrate Sequence, Carrier Proteins, Complement Activation, Computer Simulation, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Models, Molecular, Molecular Sequence Data, Magnetic Resonance Spectroscopy, Synovial Fluid, Mannose-Binding Lectins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.